Nevertheless, as this was a pilot study designed to explore the role of immunological biomarkers, such as MCP-1, in the pathophysiology of AIS and TIA, and to identify potential associations between MCP-1 levels and stroke outcomes, these limitations highlight the need for further prospective studies and randomized controlled trials with larger, more homogeneous cohorts. The gene discussed is CCL2; the disease is transient ischemic attack.